Emphasis on X-ray quality spurs adoption of radiography, finds Frost & Sullivan
The increasing popularity of retrofit systems fuels market growth
New analysis from Frost & Sullivan, Western and Eastern European Markets for Computed and Digital Radiography, finds that the market earned revenues of more than $388.8 million in 2011 and estimates this to reach $473.9 million in 2016.
The implementation of picture archiving and communications systems (PACS) will contribute to the growth of the CR and DR market in Europe, as healthcare facilities look to fully benefit from the benefits of both PACS and digital X-ray solutions.
“CR and DR technologies’ advantages over analogue X-rays, which include increased patient throughput as well as shorter examination and result analysis times, have also encouraged their adoption,” says Frost & Sullivan Healthcare Industry Analyst Dominika Grzywinska. “The shortage of radiologists further drives uptake, as digital systems enable a radiologist to cater to nearly three times the number of patients served using analogue X-rays.”
Retrofit systems, which facilitate the upgrade of existing X-ray systems without replacing the installed base, are growing popular especially in Western Europe. In fact, many end users prefer retrofit solutions offering high throughput and image quality at reasonable costs, rather than new DR systems that require added investments.
While these retrofit systems have made digitization more cost-effective and prices of both CR and DR systems continue to decline, affordability remains an issue owing to the challenging economic situation in Europe.
“Customers are placing greater emphasis on return-on-investments, looking for solutions tailored to their needs at an affordable price,” concludes Grzywinska. “Therefore, vendors need to deliver mid-range and low-end solutions that appeal to a wider range of customers and to smaller end users in particular.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.